PDCD1 and glioblastoma: Shevtsov et al. reported that combination therapy of NK cells activated by IL-2 and TDK derived from HSP70 and anti-PD1 antibody exhibited stronger cytotoxicity effects against intracranial GBM GL261 cells in vitro [194].